Research & Evidence
The Science Behind Functional Interpretation
Beyond Normal is grounded in peer-reviewed research across functional health, systems physiology, and clinical biochemistry. The functional intervals and cluster frameworks used in the platform are derived from published literature, not population averages.
Why Functional Intervals Differ from Conventional Reference Ranges
Conventional laboratory reference ranges are derived from population datasets and are designed to detect established pathology. They perform that role effectively. However, they are not designed to identify the early physiological shifts, compensatory adaptations, and subclinical patterns that present in clinical practice long before diagnostic thresholds are reached.
Functional intervals are derived from research identifying the marker values associated with optimal physiological performance rather than the absence of disease. In many cases, the gap between a conventional upper limit and a functionally meaningful threshold is clinically significant.
Beyond Normal applies these research-informed intervals alongside pattern recognition across clusters and physiological systems. A single marker rarely tells the full story. The platform is designed to surface what the pattern is signalling, not just whether an individual value sits within a broad population range.
Why Optimal Ranges Matter
Markers rarely shift in isolation. Subtle changes across multiple interconnected markers often reflect emerging physiological patterns long before any single value reaches a conventional threshold. Interpreted collectively, these shifts can provide meaningful clinical insight into how systems are interacting and where compensation is occurring.
By analysing markers in context across clusters, ratios, and physiological systems, Beyond Normal helps surface patterns that may otherwise go unrecognised within broad population ranges. The aim is not to diagnose disease. The aim is to support evidence-informed clinical reasoning and earlier intervention by qualified practitioners.
Cardiovascular Health
Research supporting optimal lipid profiles, inflammatory burden assessment, and cardiovascular risk stratification beyond standard lipid panels.
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M.-R., ... Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. European Heart Journal, 38(32), 2459-2472.
Research suggests optimal LDL levels may be lower than conventional reference ranges indicate for cardiovascular risk reduction.
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., Kastelein, J. J. P., Cornel, J. H., Pais, P., Pella, D., Genest, J., Cifkova, R., Lorenzatti, A., Forster, T., Kobalava, Z., ... Glynn, R. J. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine, 377(12), 1119-1131.
High-sensitivity C-reactive protein provides additional predictive value beyond traditional lipid measurements.
Australian and New Zealand research
Cardiovascular risk assessment in Australia and New Zealand rests on established risk calculators and the standard lipid panel. A growing body of local research examines whether other blood markers, read alongside that panel, add information about long-term risk. The studies below draw on Australian and New Zealand cohorts. Most are observational. Several were conducted in people with existing heart disease or diabetes, so their findings describe associations in those groups and are not targets for every individual.
Lipid ratios and lipoproteins
Sultani, R., Tong, D. C., Peverelle, M., Lee, Y. S., Baradi, A., & Wilson, A. M. (2020). Elevated triglycerides to high-density lipoprotein cholesterol (TG/HDL-C) ratio predicts long-term mortality in high-risk patients. Heart, Lung and Circulation, 29(3), 414-421. https://doi.org/10.1016/j.hlc.2019.03.019
In 482 Melbourne patients referred for coronary angiography and followed for an average of 5.1 years, a TG/HDL-C ratio of 2.5 or above was independently associated with higher all-cause mortality (HR 2.10, 95% CI 1.04 to 4.20). The cohort was small and high risk, so the finding may not apply to the general population.
Davis, T. M. E., Chubb, S. A. P., & Davis, W. A. (2024). The relationship between serum HDL-cholesterol, cardiovascular disease and mortality in community-based people with type 2 diabetes: The Fremantle Diabetes Study Phase 2. Cardiovascular Diabetology, 23(1), Article 362. https://doi.org/10.1186/s12933-024-02447-0
In 1,479 community-based adults with type 2 diabetes, women showed a U-shaped relationship between HDL cholesterol and both cardiovascular events and death: risk was higher below 1.04 mmol/L and above 1.59 mmol/L than at 1.04 to 1.22 mmol/L. In men there was no U-shape. Only low HDL cholesterol (below 0.90 mmol/L) was associated with higher mortality.
Carr, S. S., Hooper, A. J., Sullivan, D. R., & Burnett, J. R. (2019). Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology, 51(2), 148-154. https://doi.org/10.1016/j.pathol.2018.11.006
A review by Australian lipid specialists. It concludes that non-HDL cholesterol and apolipoprotein B are more accurate than calculated LDL cholesterol in people with high triglycerides, in non-fasting samples and at very low LDL cholesterol concentrations, and that accumulating evidence suggests both are better predictors of atherosclerotic cardiovascular disease risk.
Koskinen, J., Juonala, M., Dwyer, T., Venn, A., Thomson, R., Bazzano, L., Berenson, G. S., Sabin, M. A., Burns, T. L., Viikari, J. S. A., Woo, J. G., Urbina, E. M., Prineas, R., Hutri-Kähönen, N., Sinaiko, A., Jacobs, D., Steinberger, J., Daniels, S., Raitakari, O. T., & Magnussen, C. G. (2018). Impact of lipid measurements in youth in addition to conventional clinic-based risk factors on predicting preclinical atherosclerosis in adulthood: International Childhood Cardiovascular Cohort Consortium. Circulation, 137(12), 1246-1255. https://doi.org/10.1161/CIRCULATIONAHA.117.029726
Across four cohorts including Tasmania's Childhood Determinants of Adult Health study (2,893 participants aged 12 to 18, followed for about 23 years), adolescent lipid levels independently predicted high carotid intima-media thickness in adulthood. Adding lipids to clinic-based risk factors gave a statistically significant but clinically modest improvement in prediction.
Inflammatory markers
Dugué, P.-A., Hodge, A. M., Ulvik, A., Ueland, P. M., Midttun, Ø., Rinaldi, S., MacInnis, R. J., Li, S. X., Meyer, K., Navionis, A.-S., Flicker, L., Severi, G., English, D. R., Vineis, P., Tell, G. S., Southey, M. C., Milne, R. L., & Giles, G. G. (2022). Association of markers of inflammation, the kynurenine pathway and B vitamins with age and mortality, and a signature of inflammaging. The Journals of Gerontology: Series A, 77(4), 826-836. https://doi.org/10.1093/gerona/glab163
In 976 Melbourne Collaborative Cohort Study participants, 17 of 34 inflammation-related blood markers were associated with mortality, including IL-6, neopterin and C-reactive protein. A 10-marker "inflammaging" signature was associated with mortality (HR 1.40 per standard deviation, 95% CI 1.24 to 1.57), and the association was replicated in a Norwegian cohort.
Li, S. X., Hodge, A. M., MacInnis, R. J., Bassett, J. K., Ueland, P. M., Midttun, Ø., Ulvik, A., Rinaldi, S., Meyer, K., Navionis, A.-S., Shivappa, N., Hébert, J. R., Flicker, L., Severi, G., Jayasekara, H., English, D. R., Vineis, P., Southey, M. C., Milne, R. L., ... Dugué, P.-A. (2021). Inflammation-related marker profiling of dietary patterns and all-cause mortality in the Melbourne Collaborative Cohort Study. The Journal of Nutrition, 151(10), 2908-2916. https://doi.org/10.1093/jn/nxab231
In 770 participants from the same cohort, healthier dietary patterns were associated with lower concentrations of kynurenines, neopterin, cytokines and C-reactive protein. Blood marker scores reflecting poorer-quality diets were associated with higher all-cause mortality over a median 14.4 years of follow-up.
Hodge, A. M., Bassett, J. K., Dugué, P.-A., Shivappa, N., Hébert, J. R., Milne, R. L., English, D. R., & Giles, G. G. (2018). Dietary inflammatory index or Mediterranean diet score as risk factors for total and cardiovascular mortality. Nutrition, Metabolism and Cardiovascular Diseases, 28(5), 461-469. https://doi.org/10.1016/j.numecd.2018.01.010
In 41,513 adults followed for an average of 19 years, more Mediterranean and less inflammatory diets were associated with lower total and cardiovascular mortality (HR 1.16 for the most versus least inflammatory diet quintile, 95% CI 1.08 to 1.24). Diet was measured by questionnaire in this study, not by blood markers.
Shawki, M., Weerasooriya, N., Salib, A., Al-Fiadh, H., Zoumberis, C., Sanders, K., Weerasooriya, S., & Al-Fiadh, A. (2026). The role of biomarkers for coronary artery disease detection in an Australian rapid access chest pain assessment clinic. Journal of Clinical Medicine, 15(2), Article 832. https://doi.org/10.3390/jcm15020832
In 3,569 patients attending a Melbourne rapid access chest pain clinic, neither hs-CRP nor LDL cholesterol predicted the presence of coronary artery disease on imaging. A single marker does not identify arterial disease, and results need clinical context.
Cardiac and renal markers
Wu, Z., Pilbrow, A. P., Liew, O. W., Chong, J. P. C., Sluyter, J., Lewis, L. K., Lasse, M., Frampton, C. M., Jackson, R., Poppe, K., Camargo, C. A., Cameron, V. A., Scragg, R., & Richards, A. M. (2022). Circulating cardiac biomarkers improve risk stratification for incident cardiovascular disease in community dwelling populations. eBioMedicine, 82, Article 104170. https://doi.org/10.1016/j.ebiom.2022.104170
In 4,102 asymptomatic New Zealand adults, those in the highest fifth for high-sensitivity troponin I, troponin T or NT-proBNP had about 2.6 to 3.4 times the hazard of a first cardiovascular event compared with the lowest fifth, after adjusting for PREDICT risk factors. Adding the markers gave a small improvement in discrimination (C statistic 0.755 to 0.771). Findings were corroborated in a second cohort of 2,528.
West, M., Kirby, A., Stewart, R. A., Blankenberg, S., Sullivan, D., White, H. D., Hunt, D., Marschner, I., Janus, E., Kritharides, L., Watts, G. F., Simes, J., & Tonkin, A. M. (2022). Circulating cystatin C is an independent risk marker for cardiovascular outcomes, development of renal impairment, and long-term mortality in patients with stable coronary heart disease: The LIPID study. Journal of the American Heart Association, 11(5), Article e020745. https://doi.org/10.1161/JAHA.121.020745
In 7,863 patients with a previous acute coronary syndrome, higher baseline cystatin C was associated with major cardiovascular events over 6 years, and with cardiovascular and all-cause mortality over 16 years, independent of estimated kidney function.
Emerging research: lipidomics and novel markers
These studies use specialised laboratory methods that are not part of standard pathology panels. They are included to show where cardiovascular risk research is heading.
Wu, J., Giles, C., Dakic, A., Beyene, H. B., Huynh, K., Wang, T., Meikle, T., Olshansky, G., Salim, A., Duong, T., Watts, G. F., Hung, J., Hui, J., Cadby, G., Beilby, J., Blangero, J., Moses, E. K., Shaw, J. E., Magliano, D. J., ... Meikle, P. J. (2024). Lipidomic risk score to enhance cardiovascular risk stratification for primary prevention. Journal of the American College of Cardiology, 84(5), 434-446. https://doi.org/10.1016/j.jacc.2024.04.060
A lipidomic risk score developed in the AusDiab study (10,339 participants) and validated in the Busselton Health Study (4,492 participants) improved risk classification for people at intermediate risk compared with the Framingham Risk Score (net reclassification improvement 0.36 and 0.33 respectively).
Dakic, A., Wu, J., Wang, T., Meikle, T. G., Huynh, K., Yi, C., Beyene, H. B., Salim, A., Cinel, M., Mellett, N., Duong, T., Faulkner, A. N., van Buuren-Milne, M., Bhagwat, A., Shaw, J. E., Magliano, D. J., Watts, G. F., Hung, J., Hui, J., ... Meikle, P. J. (2026). Integration of lipidomic and polygenic risk scores within contemporary clinical cardiovascular risk assessment pathways: A multi-cohort development and validation study. eClinicalMedicine, 99, Article 104159. https://doi.org/10.1016/j.eclinm.2026.104159
Adding lipidomic and polygenic scores to AusCVDRisk across five Australian cohorts (13,521 adults) gave modest gains in discrimination overall and a larger improvement in risk classification for people at intermediate risk (net reclassification improvement 0.305, 95% CI 0.212 to 0.397).
Mundra, P. A., Barlow, C. K., Nestel, P. J., Barnes, E. H., Kirby, A., Thompson, P., Sullivan, D. R., Alshehry, Z. H., Mellett, N. A., Huynh, K., Jayawardana, K. S., Giles, C., McConville, M. J., Zoungas, S., Hillis, G. S., Chalmers, J., Woodward, M., Wong, G., Kingwell, B. A., ... Meikle, P. J. (2018). Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention. JCI Insight, 3(17), Article e121326. https://doi.org/10.1172/jci.insight.121326
In 5,991 LIPID study participants with existing heart disease, adding seven lipid species to conventional risk factors improved prediction of cardiovascular death (C statistic 0.673 to 0.727). The result was tested in a second cohort of people with diabetes.
Wang, T., Beyene, H. B., Yi, C., Cinel, M., Mellett, N. A., Olshansky, G., Meikle, T. G., Wu, J., Dakic, A., Watts, G. F., Hung, J., Hui, J., Beilby, J., Blangero, J., Kaddurah-Daouk, R., Salim, A., Moses, E. K., Shaw, J. E., Magliano, D. J., ... Meikle, P. J. (2024). A lipidomic based metabolic age score captures cardiometabolic risk independent of chronological age. eBioMedicine, 105, Article 105199. https://doi.org/10.1016/j.ebiom.2024.105199
In 14,833 Australians, people whose lipid-derived "metabolic age" most exceeded their actual age had higher 17-year all-cause mortality than those in the lowest fifth (HR 1.56, 95% CI 1.34 to 1.79).
Lee, S., Castley, A., Knuiman, M., Nolan, D., Sanfilippo, F., & Dwivedi, G. (2025). Inflammatory and vascular biomarkers as predictors of all-cause death and cardiovascular outcomes in an Australian community-based cohort. Physiological Reports, 13(11), Article e70379. https://doi.org/10.14814/phy2.70379
In 981 Busselton adults without cardiovascular disease, higher baseline soluble GDF-15, CD14 and E-selectin were associated with all-cause death and cardiovascular outcomes over 5 to 20 years of follow-up (for GDF-15 and all-cause death at 20 years, HR 1.79, 95% CI 1.24 to 2.56).
Metabolic Function
Evidence supporting tighter glycaemic control thresholds, insulin sensitivity markers, and the functional significance of results at the upper end of conventional normal ranges.
Echouffo-Tcheugui, J. B., Selvin, E. (2021). Prediabetes and what it means: The epidemiological evidence. Annual Review of Public Health, 42, 59-77.
Fasting glucose levels at the higher end of 'normal' are associated with increased risk of developing type 2 diabetes.
Welsh, C., Welsh, P., Celis-Morales, C. A., Mark, P. B., Mackay, D., Ghouri, N., Ho, F. K., Ferguson, L. D., Gray, S. R., Lyall, D. M., Gill, J. M. R., Pell, J. P., & Sattar, N. (2020). Glycated hemoglobin, prediabetes, and the links to cardiovascular disease: Data from UK Biobank. Diabetes Care, 43(2), 440-446.
Optimal HbA1c levels for disease prevention may be narrower than conventional laboratory ranges.
Thyroid & Energy
Research on subclinical thyroid dysfunction, the clinical relevance of free T3, and TSH values within conventional range that may still correlate with patient symptomatology.
Biondi, B., Cappola, A. R., & Cooper, D. S. (2019). Subclinical hypothyroidism: A review. Journal of the American Medical Association, 322(2), 153-160.
Patients with TSH levels at the higher end of normal may experience symptoms of hypothyroidism.
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., & Sawka, A. M. (2014). Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid, 24(12), 1670-1751.
Free T3 levels correlate with metabolic symptoms even within conventional reference ranges.
Histamine & Immune Response
Research on diamine oxidase activity, histamine intolerance, mast cell activation, and the clinical patterns that emerge across the histamine/immune cluster.
Maintz, L., & Novak, N. (2007). Histamine and histamine intolerance. American Journal of Clinical Nutrition, 85(5), 1185–1196. https://doi.org/10.1093/ajcn/85.5.1185
Histamine intolerance results from impaired diamine oxidase (DAO) activity, leading to an accumulation of histamine that can mimic allergic reactions including urticaria, headache, gastrointestinal symptoms, and cardiovascular effects. The review highlights how histamine-rich foods, alcohol, and certain drugs can provoke symptoms in susceptible individuals.
Kulthanan, K., Church, M. K., Grekowitz, E. M., Hawro, T., Kiefer, L. A., Munprom, K., Nanchaipruek, Y., Rujitharanawong, C., Terhorst-Molawi, D., & Maurer, M. (2022). Evidence for histamine release in chronic inducible urticaria – A systematic review. Frontiers in Immunology, 13, Article 901851. https://doi.org/10.3389/fimmu.2022.901851
This systematic review provides evidence that histamine released from mast cells plays a central role in the pathogenesis of chronic inducible urticaria, supporting the use of antihistamines as first-line treatment and highlighting the importance of understanding histamine pathways in managing urticaria subtypes.
Clinical Scope Statement
Beyond Normal is a clinical decision support tool for qualified health practitioners. The functional intervals, ratios, and cluster frameworks presented in this platform are derived from peer-reviewed research and are intended to support practitioner-led clinical reasoning.
This platform does not diagnose disease, prescribe treatment, or replace the professional judgement of a qualified clinician. All interpretation should be applied within the practitioner's scope of practice and in the context of a thorough clinical assessment.
The evidence base for functional blood analysis continues to develop. Beyond Normal is committed to ongoing literature review and refinement of its frameworks as new research emerges.
